TOP2A and adenocarcinoma: In postoperative patients who received adjuvant chemotherapy, high TopIIα expression was a prognostic marker of longer DFS (hazard ratio 0.442, 95% confidence interval 0.239-0.818, P = 0.009), whereas adenocarcinoma (hazard ratio 2.140, 95% confidence interval 1.373-3.337, P = 0.001) and later TNM stage (hazard ratio 1.688, 95% confidence interval 1.291-2.208, P < 0.001) were related to a shorter DFS as compared to non-adenocarcinoma and earlier TNM stage.